Provided by Tiger Fintech (Singapore) Pte. Ltd.

Theravance Biopharma

11.15
+0.10000.90%
Volume:65.54K
Turnover:728.21K
Market Cap:557.51M
PE:-9.40
High:11.25
Open:11.08
Low:11.00
Close:11.05
Loading ...

Theravance Biopharma Is Maintained at Buy by BTIG

Dow Jones
·
27 Jun

Theravance Biopharma (TBPH) Gets a Buy from JonesTrading

TIPRANKS
·
26 Jun

Theravance Biopharma Earns $7.5 Million Milestone Payment After COPD Drug Wins China Approval

MT Newswires Live
·
26 Jun

BRIEF-Theravance Biopharma Announces Approval Of Yupelri By China's NMPA

Reuters
·
26 Jun

Theravance Biopharma Inc - Approval Triggers $7.5 Mln Milestone Payment From Viatris

THOMSON REUTERS
·
26 Jun

Theravance Biopharma Announces Approval of Yupelri® (Revefenacin) by China's Nmpa

THOMSON REUTERS
·
26 Jun

Theravance Biopharma Initiated at Buy by Jones Trading

Dow Jones
·
17 Jun

Theravance Biopharma initiated with a Buy at JonesResearch

TIPRANKS
·
17 Jun

Promising Market Opportunity for Theravance Biopharma: Buy Rating on Ampreloxetine’s Potential in MSA Treatment

TIPRANKS
·
17 Jun

BRIEF-Theravance Biopharma - Theravance And Mylan Enter Settlement Agreement With Eugia - SEC Filing

Reuters
·
06 Jun

Theravance Biopharma Inc - Settlement Resolves Patent Litigation Against Eugia - SEC Filing

THOMSON REUTERS
·
06 Jun

Theravance Biopharma Inc. and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039

Reuters
·
06 Jun

Theravance Biopharma’s Hold Rating: Balancing Cash Influx with Long-term Growth Uncertainty

TIPRANKS
·
05 Jun

Rhonda Farnum, SVP of Comm & Medical Affairs, Reports Disposal of Common Shares in Theravance Biopharma Inc

Reuters
·
05 Jun

Theravance Biopharma’s Strategic Moves and Growth Potential Justify Buy Rating

TIPRANKS
·
03 Jun

Theravance Biopharma Sells Trelegy Royalty Interest to GSK

TIPRANKS
·
02 Jun

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

THOMSON REUTERS
·
02 Jun

Theravance Biopharma Inc - Financial Guidance for 2025 Remains Unchanged

THOMSON REUTERS
·
02 Jun

Theravance Biopharma Inc - Retains Rights to up to $150 Mln in Milestones From Royalty Pharma on Trelegy Ellipta Net Sales in 2025 & 2026

THOMSON REUTERS
·
02 Jun

Press Release: Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

Dow Jones
·
02 Jun